about
Hypertriglyceridemia and Cardiovascular Diseases: RevisitedStatins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular diseaseHistamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans.Characterization of regional cerebral blood flow and expression of angiogenic growth factors in the frontal cortex of juvenile male SHRSP and SHR.Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies.Differential metabolic effects of distinct statins.How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.How to balance cardiorenometabolic benefits and risks of statins.Lipoprotein metabolism, insulin resistance, and adipocytokine levels in Japanese female adolescents with a normal body mass index and high body fat mass.Evidence for a potential role of estrogen in the penis: detection of estrogen receptor-alpha and -beta messenger ribonucleic acid and protein.Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation.A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease.The slow cyclic GMP increase caused by serotonin in NG108-15 cells is not inhibited by antagonists of known serotonin receptors: possible existence of a new receptor subtype coupled with membrane-bound guanylate cyclase.Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals.Evidence for selective inhibition by lysophosphatidylcholine of acetylcholine-induced endothelium-dependent hyperpolarization and relaxation in rat mesenteric artery.Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats.Sources of Ca2+ in relation to generation of acetylcholine-induced endothelium-dependent hyperpolarization in rat mesenteric artery.Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery.Agonist-independent tonic inhibitory influence of Gi on adenylate cyclase activity in rabbit ventricular myocardium and its removal by pertussis toxin: a role of empty receptor-mediated Gi activation.Angiotensin converting enzyme inhibitors remain the first treatment of choice.Thapsigargin- and cyclopiazonic acid-induced endothelium-dependent hyperpolarization in rat mesenteric artery.Colestimide, an anion exchange resin agent, can decrease the number of LDL particles without affecting their size in patients with hyperlipidemia.Assessment of newly developed perfluorocarbon emulsion: oxygen carrying capacity as the blood substitute in vivo.Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).In vivo estrogen manipulations on coronary capillary network and angiogenic molecule expression in middle-aged female rats.Ovariectomy attenuates hyperpolarization and relaxation mediated by endothelium-derived hyperpolarizing factor in female rat mesenteric artery: a concomitant decrease in connexin-43 expression.Menopause and cardiovascular diseases in women.Coronary capillary network remodeling and hypofibrinolysis in aged obese diabetic rats: implications for increased myocardial vulnerability to ischemia.Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats.Regulatory molecules for coronary expressions of VEGF and its angiogenic receptor KDR in hypoestrogenic middle-aged female rats.Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women.Gonadal hormones and frontocortical expression of vascular endothelial growth factor in male stroke-prone, spontaneously hypertensive rats, a model for attention-deficit/hyperactivity disorder.A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis.Temporal effects of edaravone, a free radical scavenger, on transient ischemia-induced neuronal dysfunction in the rat hippocampus.
P50
Q26750954-2399159C-D09F-4BD2-8792-BA3E9A18A427Q26829576-CC939FB9-ACFE-4078-8B18-593FA421E71FQ30336380-3BB4C8EC-E5E7-410F-8953-3C2FA2D8ED72Q31133133-E4F8AFF3-1CD9-412A-9330-1F56C8F559D2Q34403710-0E889B15-E152-411E-ADB7-5E64DCB1C00DQ35766558-6654102C-49F8-4D7F-A47E-C6D1F6C63CDCQ37193394-BA99F310-0D1A-49E7-84F9-F962053DCA14Q37592357-221037A3-8F3B-4359-AC5A-90064955A1E1Q37815804-84075EB5-CC85-45E0-924D-C39614381D4EQ38002637-0D4387BA-EE2D-459D-8097-5756C3D8F197Q38060413-7A730263-D14E-4C02-A6C6-8F8414D5FDF9Q38224026-CC37F134-9D6B-40A5-9A1B-044CF956E793Q40010166-5AAFBD7E-7EFF-4C01-A315-19BFA36E21AEQ40620189-7BEC30B4-F7DB-4154-9629-17DD304D3014Q40707075-515DED42-145D-4672-A93B-68E098113069Q40752826-EEF3D510-EC63-4EE9-8C7F-6D59DF1FC324Q41672822-1DAB40CD-7C82-4F07-A015-5F071BF09F5EQ41735962-8A5FFACE-CB65-4ECD-BDD5-6A5E9E2B93DCQ41768532-571D9822-EF2D-44E3-B517-F4FEC1A20D23Q41821847-BE1F5D2C-ECE0-43F9-89D7-AA771D9914A9Q41847311-0EC48EB0-A415-4BE9-A6BF-C28746714956Q42051095-4E30F040-3414-40D5-9F3D-E71C0C695BADQ42438050-74B96337-9B30-44EB-9AE4-9D86BBDFDCF8Q42617282-9E61E3DD-EEB1-4534-AF63-4802165EDB6FQ42708089-CEF20798-A6A7-4DE9-81F8-621F340297F8Q43178286-FF635E1A-DD39-4EDF-9A18-BD6C658722FCQ43799416-F38546B5-E066-4B93-A039-7F7EE9608326Q43915744-766FE965-F0C0-4BA2-B75C-EC87BE57D048Q44054756-7605A834-AA01-43C9-A577-0B00C8862BC9Q44177917-F7693BF9-EB93-4FF2-A8FA-A5A1BAFEA7DBQ44228765-7787B3D6-7920-4C2B-8637-379F7C54CE7CQ44320493-279EDD8E-7A18-444C-8332-D3B3293A955BQ44518209-26399EB3-54D1-4EEE-9572-4F4AAB2AD84AQ44575150-37E40DEB-6496-4C72-8F63-771DE8A8B8C8Q44881999-0070227E-EA0F-4DDC-A2AB-5610D7C3DA7BQ44890815-C883979E-21EB-458E-BFDC-566D7F901DC4Q44912791-F3A76BB9-4330-44EA-AABE-3B1CDF9C2BFCQ44922379-961B8D64-105B-4BD6-A2A9-6ADA8CD63A00Q45990214-918407FF-25F8-4122-98F6-686826570812Q46445607-B846CC0D-91BD-429B-8E5F-4FA25E84D88C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ichiro Sakuma
@ast
Ichiro Sakuma
@en
Ichiro Sakuma
@es
Ichiro Sakuma
@nl
Ichiro Sakuma
@sl
type
label
Ichiro Sakuma
@ast
Ichiro Sakuma
@en
Ichiro Sakuma
@es
Ichiro Sakuma
@nl
Ichiro Sakuma
@sl
altLabel
Ichiro
@en
prefLabel
Ichiro Sakuma
@ast
Ichiro Sakuma
@en
Ichiro Sakuma
@es
Ichiro Sakuma
@nl
Ichiro Sakuma
@sl
P106
P1153
55349340200
P31
P496
0000-0002-3863-0492